Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

39.44
-0.1600-0.40%
Post-market: 38.66-0.7800-1.98%19:34 EST
Volume:361.58K
Turnover:14.26M
Market Cap:1.15B
PE:-90.84
High:39.87
Open:39.46
Low:39.15
Close:39.60
52wk High:40.61
52wk Low:14.59
Shares:29.19M
Float Shares:26.72M
Volume Ratio:1.02
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4342
EPS(LYR):0.6569
ROE:-2.69%
ROA:-1.72%
PB:2.46
PE(LYR):60.04

Loading ...

New Data Confirms Performance of Decisiondx®-Melanoma to Identify Patients With Less Than Five Percent Risk of Sentinel Lymph Node Positivity

THOMSON REUTERS
·
Nov 14

Castle Biosciences CFO Frank Stokes Reports Disposal of Common Shares

Reuters
·
Nov 14

Kristen M. Oelschlager, Chief Operating Officer, Reports Disposal of Castle Biosciences Inc. Common Shares

Reuters
·
Nov 14

Castle Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference

Reuters
·
Nov 11

SciBase Holding AB reports Q3 net sales of SEK 10.3 million and loss after tax of SEK 18.8 million

Reuters
·
Nov 07

Scibase and Castle Biosciences Expand Collaboration and License Agreement and Enter Into Loan Agreement of SEK 20 Million

THOMSON REUTERS
·
Nov 07

Scibase And Castle Biosciences Expand Collaboration

Reuters
·
Nov 07

SciBase Secures SEK 20 Million Loan from Castle Biosciences

Reuters
·
Nov 07

Stock Track | Castle Biosciences Soars 5.03% as BTIG Maintains Buy Rating

Stock Track
·
Nov 06

Castle Biosciences Navigates Regulatory Uncertainty Amid Shifting Policies and Trade Challenges

TIPRANKS
·
Nov 05

Castle Biosciences COO Kristen M. Oelschlager Reports Disposal of Common Shares

Reuters
·
Nov 05

Castle Biosciences Is Maintained at Outperform by Baird

Dow Jones
·
Nov 05

Stock Track | Castle Biosciences Soars 6% as Leerink Partners Boosts Price Target

Stock Track
·
Nov 04

U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx, Cardinal Health

Reuters
·
Nov 04

Castle Biosciences Inc : Leerink Partners Raises Target Price to $40 From $35

THOMSON REUTERS
·
Nov 04

Castle Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 04

Castle Biosciences raises FY25 revenue view to $327M-$335M from $310M-$320M

TIPRANKS
·
Nov 04

Stock Track | Castle Biosciences Soars 5.48% on Strong Q3 Revenue Beat

Stock Track
·
Nov 04

BRIEF-Castle Biosciences Q3 Revenue USD 83.043 Million Vs. IBES Estimate USD 71.2 Million

Reuters
·
Nov 04

Castle Biosciences Q3 Pretax Profit USD -386 Thousand

THOMSON REUTERS
·
Nov 04